Absci Earnings Reports

Absci posted lower revenue in Q3 2025 while ramping up R&D spending, resulting in a larger net loss. The company reaffirmed its focus on ABS-201 programs and highlighted progress toward clinical trials.

Absci's Q2 2025 results showed ongoing execution across internal and partnered pipelines. Despite a drop in revenue and a higher net loss, the company strengthened its balance sheet, extending runway into 2028.

Absci reported Q1 2025 revenue of $1.2M with a net loss of $26.3M, driven by increased R&D investments. The company began dosing in its ABS-101 clinical trial and strengthened its pipeline momentum.

Absci generated $0.7 million in revenue during Q4 2024, up from $0.3 million the previous year. Increased investments in R&D and continued operational activities led to a net loss of $29.0 million, as the company advances its pipeline and AI-driven drug creation platform.

Absci reported revenue of $1.7 million for Q3 2024, driven by partnered programs. The company continues to advance its internal pipeline programs and expects to advance at least one additional internal asset program to a lead stage this year. They also anticipate signing drug creation partnerships with at least four partners in 2024. Net loss was $27.4 million for the quarter, and cash, cash equivalents, and short-term investments totaled $127.1 million as of September 30, 2024.

Absci reported a decrease in revenue to $1.3 million compared to $3.4 million in the same period last year, driven by the mix of partnered and internal programs. The net loss was $24.8 million, an improvement from the $41.7 million net loss in the prior year, which included a non-cash goodwill impairment charge. The company's cash, cash equivalents, and short-term investments totaled $145.2 million.

Absci reported a revenue of $0.9 million and a net loss of $22.0 million for the first quarter of 2024. The company continues to advance its internal pipeline programs and expects to sign additional drug creation partnerships. Cash, cash equivalents, and short-term investments totaled $161.5 million as of March 31, 2024.

Absci reported Q4 2023 revenue of $0.3 million and a net loss of $23.5 million. The company highlighted its progress in AI-driven biologic drug discovery, including the initiation of IND-enabling studies for ABS-101 and a new collaboration with AstraZeneca.